Cell-Based Therapies for Stroke: Are We There Yet?

Overview

Journal Front Neurol

Specialty Neurology

Date 2019 Jul 12

PMID 31293500

Citations 26

Authors

Mirja Krause

Thanh G Phan

Henry Ma

Christopher G Sobey

Rebecca Lim

Affiliations

Soon will be listed here.

Abstract

Stroke is the second leading cause of death and physical disability, with a global lifetime incidence rate of 1 in 6. Currently, the only FDA approved treatment for ischemic stroke is the administration of tissue plasminogen activator (tPA). Stem cell clinical trials for stroke have been underway for close to two decades, with data suggesting that cell therapies are safe, feasible, and potentially efficacious. However, clinical trials for stroke account for <1% of all stem cell trials. Nevertheless, the resources devoted to clinical research to identify new treatments for stroke is still significant (53-64 million US$, Phase 1-4). Notably, a quarter of cell therapy clinical trials for stroke have been withdrawn (15.2%) or terminated (6.8%) to date. This review discusses the bottlenecks in delivering a successful cell therapy for stroke, and the cost-to-benefit ratio necessary to justify these expensive trials. Further, this review will critically assess the currently available data from completed stroke trials, the importance of standardization in outcome reporting, and the role of industry-led research in the development of cell therapies for stroke.

Citing Articles

Advancements in the mechanisms of Naotai formula in treating stroke: A multi-target strategy.

Shi Y, Ma Y, Liao J Heliyon. 2024; 10(17):e36748.

PMID: 39296232 PMC: 11408019. DOI: 10.1016/j.heliyon.2024.e36748.

Stem cell therapy: a new hope for stroke and traumatic brain injury recovery and the challenge for rural minorities in South Carolina.

Mohamed G, Lench D, Grewal P, Rosenberg M, Voeks J Front Neurol. 2024; 15:1419867.

PMID: 39184380 PMC: 11342809. DOI: 10.3389/fneur.2024.1419867.

Brain repair mechanisms after cell therapy for stroke.

Rust R, Nih L, Liberale L, Yin H, El Amki M, Ong L Brain. 2024; 147(10):3286-3305.

PMID: 38916992 PMC: 11449145. DOI: 10.1093/brain/awae204.

Preconditioning with interleukin-1 alpha is required for the neuroprotective properties of mesenchymal stem cells after ischemic stroke in mice.

Wong R, Smith C, Allan S, Pinteaux E J Cereb Blood Flow Metab. 2023; 43(12):2040-2048.

PMID: 37602422 PMC: 10925871. DOI: 10.1177/0271678X231197109.

Impact of caregivers' psychological and caregiving status on recruitment, conversion, and retention in stem cell therapy trials for cerebral palsy: A prospective survey analysis.

Huang X, Qin X, Li M, Li Y, Shen L, Jin G Nurs Open. 2023; 10(8):5293-5305.

PMID: 37431277 PMC: 10333896. DOI: 10.1002/nop2.1767.

References

Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn K, Gebel J . Transplantation of cultured human neuronal cells for patients with stroke. Neurology. 2000; 55(4):565-9. DOI: 10.1212/wnl.55.4.565. View

Chen J, Li Y, Wang L, Lu M, Zhang X, Chopp M . Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci. 2001; 189(1-2):49-57. DOI: 10.1016/s0022-510x(01)00557-3. View

Hess D, Hill W, Martin-Studdard A, Carroll J, Brailer J, Carothers J . Bone marrow as a source of endothelial cells and NeuN-expressing cells After stroke. Stroke. 2002; 33(5):1362-8. DOI: 10.1161/01.str.0000014925.09415.c3. View

Bekelman J, Li Y, Gross C . Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003; 289(4):454-65. DOI: 10.1001/jama.289.4.454. View

Ashjian P, Elbarbary A, Edmonds B, DeUgarte D, Zhu M, ZuK P . In vitro differentiation of human processed lipoaspirate cells into early neural progenitors. Plast Reconstr Surg. 2003; 111(6):1922-31. DOI: 10.1097/01.PRS.0000055043.62589.05. View

Iihoshi S, Honmou O, Houkin K, Hashi K, Kocsis J . A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Res. 2004; 1007(1-2):1-9. DOI: 10.1016/j.brainres.2003.09.084. View

Evers S, Struijs J, Ament A, van Genugten M, Jager J, van den Bos G . International comparison of stroke cost studies. Stroke. 2004; 35(5):1209-15. DOI: 10.1161/01.STR.0000125860.48180.48. View

Ingall T . Stroke--incidence, mortality, morbidity and risk. J Insur Med. 2004; 36(2):143-52. View

Wislet-Gendebien S, Bruyere F, Hans G, Leprince P, Moonen G, Rogister B . Nestin-positive mesenchymal stem cells favour the astroglial lineage in neural progenitors and stem cells by releasing active BMP4. BMC Neurosci. 2004; 5:33. PMC: 520747. DOI: 10.1186/1471-2202-5-33. View

10.

Savitz S, Dinsmore J, Wechsler L, Rosenbaum D, Caplan L . Cell therapy for stroke. NeuroRx. 2005; 1(4):406-14. PMC: 534949. DOI: 10.1602/neurorx.1.4.406. View

11.

Cho K, Trzaska K, Greco S, McArdle J, Wang F, Ye J . Neurons derived from human mesenchymal stem cells show synaptic transmission and can be induced to produce the neurotransmitter substance P by interleukin-1 alpha. Stem Cells. 2005; 23(3):383-91. DOI: 10.1634/stemcells.2004-0251. View

12.

Wislet-Gendebien S, Hans G, Leprince P, Rigo J, Moonen G, Rogister B . Plasticity of cultured mesenchymal stem cells: switch from nestin-positive to excitable neuron-like phenotype. Stem Cells. 2005; 23(3):392-402. DOI: 10.1634/stemcells.2004-0149. View

13.

Bang O, Lee J, Lee P, Lee G . Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005; 57(6):874-82. DOI: 10.1002/ana.20501. View

14.

Savitz S, Dinsmore J, Wu J, Henderson G, Stieg P, Caplan L . Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study. Cerebrovasc Dis. 2005; 20(2):101-7. DOI: 10.1159/000086518. View

15.

Kondziolka D, Steinberg G, Wechsler L, Meltzer C, Elder E, Gebel J . Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. J Neurosurg. 2005; 103(1):38-45. DOI: 10.3171/jns.2005.103.1.0038. View

16.

Shen L, Li Y, Chen J, Zhang J, Vanguri P, Borneman J . Intracarotid transplantation of bone marrow stromal cells increases axon-myelin remodeling after stroke. Neuroscience. 2005; 137(2):393-9. DOI: 10.1016/j.neuroscience.2005.08.092. View

17.

Drummond M, Davies L, Ferris 3rd F . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Soc Sci Med. 1992; 34(9):973-81. DOI: 10.1016/0277-9536(92)90128-d. View

18.

Patsopoulos N, Ioannidis J, Analatos A . Origin and funding of the most frequently cited papers in medicine: database analysis. BMJ. 2006; 332(7549):1061-4. PMC: 1458565. DOI: 10.1136/bmj.38768.420139.80. View

19.

Lindvall O, Kokaia Z . Stem cells for the treatment of neurological disorders. Nature. 2006; 441(7097):1094-6. DOI: 10.1038/nature04960. View

20.

Guzman R, Choi R, Gera A, De Los Angeles A, Andres R, Steinberg G . Intravascular cell replacement therapy for stroke. Neurosurg Focus. 2008; 24(3-4):E15. DOI: 10.3171/FOC/2008/24/3-4/E14. View